United States
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2019 and strategically headquartered in the United States, located in New York City and Waltham, Massachusetts. Their slogan, "Unlocking the full potential of complement therapeutics through the power of selectivity," highlights their focus on developing novel therapeutics.
The company specializes in designing and delivering next-generation monoclonal antibodies with enhanced selectivity and potency. This innovative biopharmaceutical approach seeks to provide transformative medicines targeting severe autoimmune and inflammatory diseases—areas with substantial unmet medical needs.
In its most recent financial milestone, Dianthus Therapeutics secured a significant $230.00 million Post-IPO Equity investment on 22 January 2024. The funding round saw participation from prominent investors such as Ally Bridge Group, Logos Capital, Octagon Capital Advisors, and Bain Capital Life Sciences, showcasing strong investor confidence in the company's potential.
Imcyse SA
